ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
9
views
0
references
Top references
cited by
0
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
3,310
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
P11 Afatinib in Patients with EGFR Mutation-Positive (EGFRm+) NSCLC Harboring Uncommon Mutations: Overview of Clinical Data
Author(s):
O. Arrieta
,
P. De Marchi
,
N. Yamamoto
,
C. Yu
,
S.I. Ou
,
C. Zhou
,
M. Paskevicius
,
A. Märten
,
Y. Wu
Publication date
Created:
September 2018
Publication date
(Print):
September 2018
Journal:
Journal of Thoracic Oncology
Publisher:
Elsevier BV
Read this article at
ScienceOpen
Publisher
Further versions
open (via crossref license)
Powered by
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
ScienceOpen Clinical Case Reports Collection
Author and article information
Journal
Title:
Journal of Thoracic Oncology
Abbreviated Title:
Journal of Thoracic Oncology
Publisher:
Elsevier BV
ISSN (Print):
15560864
Publication date Created:
September 2018
Publication date (Print):
September 2018
Volume
: 13
Issue
: 9
Page
: S165
Article
DOI:
10.1016/j.jtho.2018.07.050
SO-VID:
4c986741-1fc0-42d9-874f-07654e06f072
Copyright ©
© 2018
License:
https://www.elsevier.com/tdm/userlicense/1.0/
History
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
3,310
Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Authors:
M.J. Hochmair
,
A. Morabito
,
D Hao
…
Common and rare EGFR mutations (EGFRm) in the RADIANT trial: final follow-up with 5 year data
Authors:
Fa,EWEEANK Shepherd
,
Frances Shepherd
,
Wilfried Eberhardt
…
1522P Real-world (RW) treatment patterns and outcomes for second-line (2L) therapy and beyond in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC receiving a first-line (1L) first- or second-generation (1G/2G) EGFR tyrosine kinase inhibitor (TKI)
Authors:
R Shah
,
N. Girard
,
SP Nagar
…
See all similar